Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy.

Int J Clin Oncol · 2024 · PMC10963556 · PMID 38334897

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

Furthermore, among patients who showed the best response to CR/CRi, those with post-treatment WT1 mRNA negative values (n = 7) showed a trend toward better OS and EFS than those without post-treatment WT1 mRNA negative values (n = 8) (median OS, 482 days vs. 364 days, p = 0.08; median EFS, NR vs. 160 days, p = 0.06) (Fig. 5 E, F).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.